• GI toxicity hits midstage Sanofi GLP-1 drug as patients drop out fiercebiotech
    April 28, 2018
    Sanofi said gastrointestinal concerns have made its experimental GLP-1 phase 2 drug SAR425899 “not acceptable for clinical use,” but it is undertaking new tests to try to get around dosing issues, which it blames for the AEs.
PharmaSources Customer Service